EVALUASI BIAYA KEMOTERAPI PASIEN EARLY BREAST CANCER DI RSUD TUGUREJO SEMARANG PERIODE JULI-DESEMBER 2018
DOI:
https://doi.org/10.61740/jcp2s.v1i1.1Keywords:
Direct medical cost, Cost of chemotherapy, Breast cancerAbstract
Early breast cancer (EBC) is defined as with or without in a breast cancer, but it has not metastasized to wider tissue. Chemotherapy expense has 59% portion of the total cost of cander patients at the hospital. There were 137 EBC patients visit during January-March 2018 conducted at Tugurejo Regional Hospital Semarang. Therefore, research is needed to evaluate the cost of chemotherapy in EBC patient in Tugurejo Hospital Semarang. This study was an observational descriptive study with a cross sectional study design. Data sources were gained from Medical Record (MR) data and billing / billing data for National Health Insurance (JKN) participant patients with an EBC diagnosis undergoing chemotherapy at Tugurejo Hospital Semarang in the period July-December 2018. The inclusion criteria for this study was JKN patients with EBC diagnosis age 17 -65 years who did chemotherapy at Tugurejo General Hospital Semarang in the period July-December 2018. Data was processed qualitatively and quantitatively. The results of evaluation of the cost of chemotherapy for EBC patients at Tugurejo Hospital Semarang in the period July-December 2018 were done with the regimen Doxorubicin-Doxetacel-Fluorouracil (AT-F) Rp 3.683.388,00 ± 193.960, Doxetacel-Epirubicin-Fluorouracil (TE-F) Rp 4.342.914 00 ± 37.614, Fluorouracil-Epirubicin-Cyclofosphamid (FEC) Rp 2.929.464,00 ± 193.960, Fluorouracil-Doxorubicin-Cyclofosphamid (FAC) amounting to Rp2.471.671,00 ± 193.960.
References
Anggraeni,I. 2009. Peran Albumin dalam Penatalaksanaan Sirosis Hati. Departemen Ilmu Penyait Dalam .Jakarta
Coleman, M. P., 2008. Cancer survival in five continents: a worldwide population-based study (Concord). The Lancet Oncology, Vol. 9(8) : pp 730-75.
Depkes RI. 2008. Pedoman Pelaksanaan Jaminan Kesehatan Masyarakat. Depkes RI. Jakarta.
Depkes RI. 2009. Undang-Undang Republik Indonesia Nomor 44 Tahun 2009 Tentang Rumah Sakit. Departemen Kesehatan Republik Indonesia. Jakarta.
Emilia, O., 2010. Bebas Ancaman Kanker Serviks. Media Presindo. Yogyakarta
Fajar, S., dan Andayani T. M., 2014. Analisis Biaya terapi pada Pasien Kanker Payudara Rawat Inap yang Menjalani Kemoterapi di RSUP Dr. Sardjito Yogyakarta Tahun 2012. Skripsi. Yogyakarta: Universitas Gadjah Mada.
Maniadakis, N., Dafni. U., Fragoulakis, V., Grimani. I., Galani. E., Fragkoulidi, A., 2009. Economic evaluation of taxane based First Line Chemotherapy in the Treatment of Patient with Metastatic Breast cancer in Greece; An analisysis alongside a multicenter, randomized phase III clinical trial. Ann. Oncol.20.278-285.
Narang, A.S., dan Desai, D.S., 2009, “Anticancer Drug Development Unique Aspects of Pharmaceutical Developmen”t, dalam Pharmaceutical Perspectives of Cancer Therapeutics diedit oleh Lu, Y., dan Mahato, R.I., Springer Science, Berlin, 49-62.
Pergub Jateng. 2017. Tarif Pelayanan Pada Badan Layanan Umum Daerah Rumah Sakit Umum Daerah dan Rumah Sakit Jiwa Daerah Provinsi Jawa Tengah. Peraturan Gubernur Jawa Tengah.
Purnamasari, V., Andayani, T.M., Fudholi, A, 2015. Analisis Biaya Terapi pada Pasien Kanker Payudara dengan Terapi Hormon. Jurnal Manajemen dan Pelayanan Farmasi (JMPF).Vol.5 No. 1.ISSN:2088-8139
Susan, 2008. Facts For Life Chemotherapy. http://ww5.komen.org/uploadedFiles/
Content_Binaries/806-388a.pdf (diakses tanggal 1 Mei 2019)
Yustiana, O., 2013. Kanker Payudara dan SADARI. PT. Nuha Medica. Yogyakarta.
Zoli, W., Ulivi, P., Tesei, A., Fabbri, F., Rosetti, M., Maltoni, R, dkk., 2005. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res.2005;7(5):R681-9. Available from: https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr1274 diakses pada 20 Mei 2019.
Zulkarnain, I., Surarso, B., Purnami, N., 2017. Penurunan Hemoglobin, Neutrofil, dan Trombosit Pasca Kemoterapi Cisplatin-Paclitacel pada Penderita Tumor Ganas Kepala dan Leher. Jurnal THT - KL Vol 10.
